Novartis Announces Positive CHMP Opinion For Kisqali
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...
Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by ...
As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...
Not every company is jumping onto the bandwagon and investing into weight loss drugs, however. One of the largest healthcare ...
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...
BP’s program includes a novel PSMA-binding molecule that may be a potential next-generation radioligand therapy (RLT) for prostate cancer and is currently being studied in two investigator-initiated ...
A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...
Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will ...
EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Saturday, October 19, 202 ...
Bronchiectasis is a clinical condition defined as a chronic, abnormal dilation of the bronchi accompanied by classical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback